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Abstract
Background: National Institute of Health and Clinical Excellence (NICE) guidance stated that a
new form of non-steroidal anti-inflammatory drug (NSAID) (selective COX-2 inhibitors) should
only be an option for arthritis patients at high risk of a gastro-intestinal (GI) event. Total
expenditure on NSAIDs has risen by 57% over five years, to £247 million in 2004. We assess
whether this expenditure increase can be accounted for by substitution – an increased prescribing
of two (more expensive) selective COX-2 inhibitors (celecoxib and rofecoxib) and a simultaneous
equivalent reduction in the prescribing volume of three (cheaper) older NSAIDs (diclofenac,
ibuprofen and naproxen).
Methods: Quarterly prescription data was collated from January 1999 to September 2004. Over
this period, the level of correlation between the total prescribing volumes for i) celecoxib and
rofecoxib, and ii) diclofenac, ibuprofen, and naproxen were compared, the change in total
expenditure on the five NSAIDs was also estimated. The latter was apportioned into that which
was estimated to have arisen due to i) substitution, and ii) increased NSAID prescription volume.
Results: Total prescription volumes for the two NSAID groups were negatively correlated (r = -
0.97, p < 0.001). In the last quarter there were 1.23 million prescriptions for celecoxib and
rofecoxib, and 0.46 million fewer prescriptions for naproxen, diclofenac, and ibuprofen (than in the
first quarter, when celecoxib and rofecoxib were not prescribed). Total expenditure for the five
NSAIDs was £32.7 million higher in the last quarter, than the first, £12.2 million of which was
estimated to be due to substitution, and £20.4 million due to increased volume.
Conclusion: The introduction of celecoxib and rofecoxib was associated with a reduction in the
prescription volume for naproxen, diclofenac, and ibuprofen. However, overall quarterly
prescription volume for these five NSAIDs increased by 0.76 million, and we estimate that quarterly
expenditure increased by £20.4 million more than would have been expected if overall NSAID
volume had remained constant. This suggests that the prescription of both celecoxib and rofecoxib
may have 'leaked' to population groups who would not previously have received an older NSAID.
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Background
Non-steroidal anti-inflammatory drugs (NSAIDs) are
used extensively in the health service to relieve conditions
that have an inflammatory component, and to relieve
pain. In England, over 20 million NSAID treatments were
prescribed in 2004, and NSAID expenditure amounted to
£247 million (3.1% of annual prescription expenditure)
[1].
NSAIDs can however induce adverse events – in the
United Kingdom (UK) it has been estimated that each
year they cause 3,500 adverse gastro-intestinal (GI) events
(perforations, ulcers, bleeds, etc.) which require hospital-
isation, and 400 deaths [2]. A gastro-protective agent
(GPA) can be co-prescribed in an attempt to reduce the
risk of a GI event, however, more recently, a new form of
NSAID (the selective cyclooxygenase-2 (COX-2) inhibi-
tor) has been developed. Selective COX-2 inhibitors aim
to inhibit the COX-2 enzyme (which is responsible for
inflammation), without inhibiting the COX-1 enzyme
(which helps to protect the mucosa lining of the stomach
and other parts of the gastro-intestinal tract) [3]. In con-
trast, older NSAIDs inhibit both the COX-2 and COX-1
enzymes, thus creating increased risk of adverse GI events.
In 2000, the National Institute of Clinical and Health
Excellence (NICE) undertook an assessment of the availa-
ble evidence on the health benefits and costs of selective
COX-2 inhibitors for arthritis patients [4]. Though the
assessment found no evidence that any of the (four) COX-
2 inhibitors were clinically superior to one another, it did
conclude that selective COX-2 inhibitors had equivalent
efficacy to NSAIDs (in terms of their ability to reduce pain
and improve physical functioning) and that selective
COX-2 inhibitors were associated with fewer GI events
than other NSAIDs [4]. On the basis of this evidence,
NICE recommended that selective COX-2 inhibitors
should not be routinely used (in preference to an older
NSAID) by patients with arthritis, but that they should be
an option for those who are at high risk of a GI event [5].
By December 2004 annual expenditure on selective COX-
2 inhibitors had grown to over £150 million in England,
and overall NSAID expenditure was approximately £65
million higher than in 2001 [1].
In this paper we seek to determine whether the aforemen-
tioned increase in overall NSAID expenditure can be
accounted for by substitution i.e. the increased prescrib-
ing of (more expensive) selective COX-2 inhibitors and a
simultaneous equivalent reduction in the prescribing vol-
ume of (cheaper) older NSAIDs. An alternative result of
increased overall NSAID prescription volume – where the
number of selective COX-2 inhibitor prescriptions has
increased by a greater amount than the associated reduc-
tion in the number of older NSAID prescriptions – might
indicate that selective COX-2 inhibitors were being pre-
scribed to certain population groups who would not pre-
viously have been prescribed an older NSAID.
O'Brien [6] has used the term 'leakage' to refer to the situ-
ation where once an intervention is provided for a specific
indication and population group (for whom there is evi-
dence of cost-effectiveness) it can 'leak' to other groups for
whom it was not originally intended (and for whom it
may also be less cost-effective). An example of leakage was
given by Lopert [7], who pointed out that ACE inhibitors
are more cost-effective for cardiac failure than for hyper-
tension (they provide no clear benefit over beta blockers,
but are considerably more expensive). Similarly, a retro-
spective examination of the appropriateness of proton
pump inhibitor (PPI) prescribing found that in 49.8% of
the cases examined patients who were prescribed a PPI did
not meet the Australian government Pharmaceutical Ben-
efits Scheme (PBS) prescribing criteria, criteria which was
drawn up to restrict the use of PPIs on the grounds of cost-
effectiveness [8]. More recently, NICE has recommended
that herceptin be an option for women with advanced
stage breast cancer [9], but women with early stage breast
cancer are now also receiving the drug, even though her-
ceptin is yet to be licensed for use, or evaluated in terms of
cost-effectiveness, in this population group [10].
As well as recommending that selective COX-2 inhibitors
only be an option for patients with arthritis who are at
high risk of an adverse GI event, NICE also estimated that
switching high-risk arthritis patients to selective COX-2
inhibitors would lead to an annual incremental expendi-
ture of approximately £25 million to the National Health
Service (NHS) [5]. This NICE guidance is consistent with
other studies which have estimated that, compared to
older NSAIDs, selective COX-2 inhibitors have a higher
incremental cost, and that their provision is only cost-
effective for groups at high risk of a GI event [11,12]. In
this paper, we compare actual increases in overall NSAID
expenditure to the £25 million per annum predicted by
NICE. Evidence of expenditure increases beyond those
that were predicted may also suggest that the provision of
selective COX-2 inhibitors had leaked to population
groups for whom its provision was not originally
intended.
Specific approach
In this paper we use data on the number of prescriptions,
and their associated expenditure, as calculated by the Pre-
scription Pricing Authority (PPA) (the PPA is responsible
for processing all NHS prescriptions that are dispensed by
any community pharmacy or dispensing doctor in Eng-
land). Data for two selective COX-2 inhibitors (celecoxib
and rofecoxib) and three older NSAIDs (diclofenac, ibu-
profen, and naproxen) were collated. These two particularCost Effectiveness and Resource Allocation 2006, 4:9 http://www.resource-allocation.com/content/4/1/9
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selective COX-2 inhibitors were chosen as they accounted
for 78% of all selective COX-2 inhibitor prescription
items in 2004 [1]. Similarly, diclofenac, ibuprofen, and
naproxen were chosen as in 1998 (prior to the use of
celecoxib and rofecoxib in England) they accounted for
77% of all NSAID prescription items [13]. In addition,
diclofenac and ibuprofen were the comparators used in
the largest randomised controlled trial (N = 8059)
designed to assess the efficacy of celecoxib [14], and
naproxen was the comparator used in the largest ran-
domised controlled trial (N = 8076) designed to assess the
efficacy of rofecoxib [15]. Data from both these clinical
trials were submitted to the United States (US) Federal
Drug Administration (FDA) for the purposes of licensing
celecoxib and rofecoxib, respectively.
Methods
NSAID prescription volume
PPA data, for England, on the number of prescriptions for
each individual NSAID were collated for quarterly (3
month) periods from January 1st 1999 (prior to the use of
celecoxib and rofecoxib) to September 30th 2004: 23 quar-
ters in total. Total quarterly prescription volumes for i) the
two selective COX-2 inhibitors (celecoxib and rofecoxib),
and ii) the three older NSAIDs (diclofenac, ibuprofen,
and naproxen) were calculated for each of the 23 quarters.
Bi-variate (Pearson) correlations were undertaken to com-
pare total prescriptions volumes for the two selective
COX-2 inhibitors to total prescription volumes for the
three older NSAIDs over the 23 quarter period. Changes in
the absolute prescription volume for both these groups
were also calculated by comparing prescription volumes
in the first quarter (ending March 1999) to those in the
last quarter (ending September 2004).
NSAID expenditure
PPA total prescription expenditure data, for England, was
collated for the two selective COX-2 inhibitors (celecoxib
and rofecoxib) and three older NSAIDs (diclofenac, ibu-
profen, and naproxen) for the 23 quarters between Janu-
ary 1999 and September 2004. Similarly, the total
increase in expenditure for the five NSAIDs, between the
first and last quarter, was calculated. To account for the
fact that, over time, higher NSAID prescription costs could
have accounted for some of the increase in NSAID
expenditure we also compared the average prescription
cost for diclofenac, ibuprofen and naproxen in the last
quarter to that in the first quarter. Average prescription
costs, for each NSAID, were estimated by dividing the
actual total prescription expenditure for the particular
NSAID (in a particular time period) by the actual number
of prescriptions made for the same NSAID (in the same
time period).
Using the following methods, we also estimated the
approximate increase in NSAID expenditure that arose
due to i) substitution, and ii) increased NSAID prescrip-
tion volume. To estimate the former, the reduction in the
number of prescriptions for the three older NSAIDs
(between the first and last quarter) was identified, and we
assumed that the total number of selective COX-2 inhibi-
tor prescriptions in the final quarter was equivalent to this
reduction (i.e. that the total number of prescriptions for
the five NSAIDs had remained constant between the first
and last quarter), and that an equivalent number of pre-
scriptions for celecoxib and rofecoxib were made. These
quarterly prescription volumes for celecoxib and
rofecoxib were then multiplied by their respective average
prescription costs (for the last quarter), and summed
together, in order to estimate what the total expenditure
on the two selective COX-2 inhibitors (in the last quarter)
would have been if the total number of prescriptions for
the five NSAIDs had remained constant. This estimate of
the expenditure on the two selective COX-2 inhibitors
(based on constant NAID volume) was then added to the
actual expenditure on diclofenac, ibuprofen and
naproxen (in the last quarter) in order to estimate what
the total expenditure on these the five NSAIDs would have
been (in the last quarter), if the total prescription volume
for these five NSAIDs had remained constant. Thus, the
approximate increase in NSAID expenditure that arose
due to substitution was then calculated by deducting the
actual expenditure on the five NSAIDs in the first quarter,
from the estimated expenditure on the five NSAIDs in the
last quarter, based on a constant volume of prescriptions
for these five NSAIDs.
The approximate increase in NSAID expenditure that
arose due to increased NSAID prescription volume was
estimated by deducting the previous (substitution) esti-
mate of what the total expenditure on the five NSAIDs
would have been in the final quarter (based on a constant
nsaid volume) from the actual total expenditure on the
five NSAIDs (in the final quarter). The increase in NSAID
expenditure was thereby divided into that which was esti-
mated to be accounted for by substitution (falling total
diclofenac, ibuprofen, and naproxen volume), and that
which could not (i.e. that which was a result of increasing
overall NSAID volume). Finally, we compared these esti-
mates to the NICE estimate that switching high-risk arthri-
tis patients to selective COX-2 inhibitors would lead to an
annual incremental NSAID expenditure of approximately
£25 million.
Results
NSAID prescription volume
By the last quarter (ending September 2004) prescription
volumes for celecoxib and rofecoxib had reached levels of
606,409 and 620,790 items per quarter respectively (Fig-Cost Effectiveness and Resource Allocation 2006, 4:9 http://www.resource-allocation.com/content/4/1/9
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ure 1). Figure 1 also shows that between the first quarter
(ending March 1999) and the last quarter the number of
prescriptions for ibuprofen and naproxen fell, but that the
number of prescriptions for diclofenac remained rela-
tively stable. Indeed between the first and last quarter total
prescription volume for the two selective COX-2 inhibi-
tors (celecoxib and rofecoxib) increased to 1.23 million
per quarter, whilst prescription volumes for the three
older NSAIDs (diclofenac, ibuprofen and naproxen) fell
from 3.55 million to 3.09 million (Figure 2).
Total prescription volumes for the two selective COX-2
inhibitors, and three older NSAIDs were highly negatively
correlated (r = -0.97, p < 0.001). Despite this, prescription
volumes for three older NSAIDs fell by only 460,084
items per quarter between the first and last quarter,
whereas the total number of prescriptions for two selec-
tive COX-2 inhibitors grew to 1,227,199 per quarter over
the same period (Figure 2). As a consequence the cumula-
tive number of prescriptions for the five NSAIDs grew
from 3,550,249 in the first quarter to 4,317,364 in the last
quarter – an increase of over 0.76 million items per quar-
ter.
NSAID prescription expenditure
By the end of September 2004, expenditure on celecoxib
and rofecoxib amounted to £15,430,892 per quarter and
£17,221,195 per quarter, respectively, (Figure 3). Con-
versely, total expenditure on the three older NSAIDs fell
from £26,583,346 in the first period to £18,671,535 in
the final quarter (Figure 4). As such, over the 23 quarter
period, overall expenditure on the five NSAIDs increased
from £26,061,182 per quarter to £51,323,622 per quarter
(Figure 4), an increase of £25.3 million per quarter. In the
Individual NSAID quarterly NHS prescription volume England for the five NSAIDs (celecoxib, rofecoxib, diclofenac, ibuprofen  and naproxen) between January 1999 and September 2004 Figure 1
Individual NSAID quarterly NHS prescription volume England for the five NSAIDs (celecoxib, rofecoxib, diclofenac, ibuprofen 
and naproxen) between January 1999 and September 2004.
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first quarter the average prescription costs for diclofenac,
ibuprofen and naproxen were £11.53, £2.33 and £8.11,
respectively, compared to £7.89, £2.71 and £7.02, respec-
tively, in the last quarter. As these average prescription
costs have generally fallen the increase in total NSAID
expenditure can not be accounted for by an increase in
average prescription costs (though the possibility that
lower costs led to a higher volume than might otherwise
have been the case can not be discounted). The average
prescription costs for celecoxib and rofecoxib were £17.65
and £22.47 when they were first prescribed (in the quar-
ters ending June 2000, and June 1999, respectively), com-
pared to £25.45 and £27.74 in the final quarter.
To estimate the approximate increase in total NSAID
expenditure that arose due to substitution we assumed
that 230,042 prescriptions for both celecoxib and
rofecoxib would have been made in the last quarter (pre-
scription volume for diclofenac, ibuprofen and naproxen
fell by 460,084 per quarter between the first and last quar-
ter). By multiplying these volumes by the average pre-
scription costs of £25.45 and £27.74, the total
expenditure on celecoxib and rofecoxib would have been
estimated to be £5,853,728 and £6,381,543, respectively
(a combined total expenditure of £12,235,271 for the two
selective COX-2 inhibitors). By adding this combined
total expenditure to the actual expenditure on the three
older NSAIDs in the final quarter (£18,671,535) we esti-
mated that the expenditure on the five NSAIDs would
Total NSAID quarterly NHS prescription volume for England for i) celecoxib and rofecoxib, ii) diclofenac, ibuprofen, and  naproxen, and iii) all five NSAIDs between January 1999 and September 2004 Figure 2
Total NSAID quarterly NHS prescription volume for England for i) celecoxib and rofecoxib, ii) diclofenac, ibuprofen, and 
naproxen, and iii) all five NSAIDs between January 1999 and September 2004.
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have been £30,906,806 (if NSAID volume had remained
constant between the first and last quarter). The actual
expenditure on the five NSAIDs was £26,061,182 in the
first quarter, thus we estimate that the approximate
increase in NSAID expenditure that arose due to substitu-
tion was £4,845,625 per quarter (equivalent to
£19,382,498 per annum).
To estimate of the approximate increase in NSAID
expenditure that arose due to increased NSAID prescrip-
tion volume, between the first and last quarter, we
deducted the value of £30,906,806 (the estimated
expenditure for the five NSAIDs based on constant vol-
ume) from the actual expenditure on the five NSAIDs in
the last quarter (£51,323,622). Thus we estimate that the
actual expenditure on the five NSAIDs was £20,416,816
per quarter higher than we estimate the expenditure on
the five NSAIDs would have been if the last quarter total
prescription volume for the five NSAIDs had been equiv-
alent to that in the first quarter, and that increased volume
accounted for 81% of the increase in NSAID expenditure.
This largely arose because, based on a constant volume,
total expenditure on the two selective COX-2 inhibitors
would have been estimated to be £12,235,271 in the last
quarter, whereas it actually amounted to £32,652,087 in
the last quarter.
Discussion
It has been shown that the introduction of two newer
NSAIDs (celecoxib and rofecoxib) was associated with a
fall in total prescription volume for three older NSAIDs
(diclofenac, ibuprofen, and naproxen). However, for the
five NSAIDs overall there were 0.76 million more pre-
scriptions in the last quarter, compared to the first, and
expenditure rose by £25.3 million per quarter (equivalent
to an increase of over £100 million per annum).
Individual NSAID quarterly NHS expenditure for England for the five NSAIDs (celecoxib, rofecoxib, diclofenac, ibuprofen and  naproxen) between January 1999 and September 2004 Figure 3
Individual NSAID quarterly NHS expenditure for England for the five NSAIDs (celecoxib, rofecoxib, diclofenac, ibuprofen and 
naproxen) between January 1999 and September 2004.
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Had the volume of prescriptions for the five NSAIDs
remained constant over the 23 quarter period we estimate
that due to substitution (from cheaper NSAIDs to more
expensive selective COX-2 inhibitors) expenditure would
have been £30.9 million in the last quarter, compared to
£26.1 million in the first quarter (the difference of £4.85
million per quarter is equivalent to an annual increase of
approximately £19.4 million). NICE estimated that
switching high-risk arthritis patients to selective COX-2
inhibitors would increase NSAID expenditure by £25 mil-
lion per annum. This figure is comparable to the increase
in NSAID expenditure that we estimated was due to sub-
stitution (£19.4 million). The higher increase estimate by
NICE may be partially explained by the fact that expendi-
ture on the five NSAIDs in the quarter prior to the NICE
report (quarter ending June 2001) was £23.1 million,
compared to £26.1 million in the first quarter of our data
set, and by the fact that our expenditure estimates were
based on only two selective COX-2 inhibitors, compared
to the four used by NICE [5]. Either way, the NICE esti-
mate that switching patients to selective COX-2 inhibitors
would increase NSAID expenditure by £25 million per
annum is substantially below the actual increase in
NSAID expenditure, which we estimated to be equivalent
to over £100 million (for the five NSAIDs, between Janu-
ary 1999 and September 2004). Indeed we estimated that
81% of the increase in NSAID expenditure was due to
increased NSAID volume.
Explanations
In randomised trials the estimated number of adverse GI
events for people taking the NSAIDs of naproxen or ibu-
profen has been estimated to be between two and four
times higher than the number for people taking rofecoxib
[15-18]. Similarly, people taking diclofenac or ibuprofen
were estimated to suffer between two and three times the
number of adverse GI events as those taking celecoxib
[14]. Consequently, it is not surprising that the release of
Total NSAID quarterly NHS expenditure for England for i) celecoxib and rofecoxib, ii) diclofenac, ibuprofen, and naproxen,  and iii) all five NSAIDs between January 1999 and September 2004 Figure 4
Total NSAID quarterly NHS expenditure for England for i) celecoxib and rofecoxib, ii) diclofenac, ibuprofen, and naproxen, 
and iii) all five NSAIDs between January 1999 and September 2004.
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celecoxib and rofecoxib coincided with a reduction in the
number of prescriptions for naproxen and ibuprofen. We
can not readily explain why prescriptions levels for
diclofenac remained largely unchanged over the six year
period, though the fact that the average prescription cost
of diclofenac fell by 32% during this time may be a con-
tributory factor. As overall volume for the five NSAIDs has
increased by 0.76 million items per quarter this may how-
ever suggest that both celecoxib and rofecoxib could have
leaked to population groups who would not previously
have received a NSAID. People may not have been pre-
scribed NSAIDs previously because, even though they
were in pain, the potential benefits were judged not to
outweigh the risk of an adverse GI event – a situation
which presumably changed with the arrival of celecoxib
and rofecoxib.
Comparisons with other studies
Our results are in line with those from two recent studies.
Joshua et al. [19] found that use of selective COX-2 inhib-
itors by rheumatology patients increased from 18% (3
months after their release) to 57% (16 months after their
release). During the same period prescription rates for
other NSAIDs fell from 43% to 20%. Moreover, Joshua et
al. [19] found that prescribing patterns for selective COX-
2 inhibitors were largely unrelated to the patient's esti-
mated risk of an adverse GI event. Similarly, Dai et al. [20]
found that 35% of patients at the lowest risk for adverse
events from NSAIDs received a COX-2 inhibitor in 2002,
compared to just 12% in 1999. In addition, when discuss-
ing the use of selective COX-2 inhibitors, the US Food and
Drug Administration (FDA) concluded that they had been
"...prescribed for indications and patients far beyond their
original intent" [21].
Study weaknesses
One of the main weaknesses of this study is that we have
looked at prescription items, and not the number of
patients taking each individual NSAID. Moreover, the
number of prescription items does not take account of the
dosage or quantity of the drug prescribed [22]. Thus
though we know that the number of prescriptions for the
five NSAIDs has increased by 0.76 million items per quar-
ter we can not be sure that more patients have been pre-
scribed a NSAID (it may be that the same patients are
receiving more prescriptions than previously). Moreover
this increased volume could be due to confounding fac-
tors that have not been controlled for in this 6 year study
period. For example, it has been estimated by Harkness et
al. [23] that over the past 40 years the prevalence of mus-
culoskeletal pain has increased by between 2 and 4 fold,
though it was acknowledged that this could be due to
increased awareness and reporting. Either way, this means
that some other factor (e.g. increased prevalence), rather
than the release of celecoxib and rofecoxib, could partially
account for the increased volume of NSAID prescriptions.
That said, weight is added to the argument that there is a
substitution effect between selective COX-2 inhibitors
and older NSAIDs, by the fact that prescription volumes
for diclofenac, ibuprofen and naproxen were increasing
prior to the fall that occurred after the release of celecoxib
and rofecoxib (in total, there were 14.42 million prescrip-
tions for these three older NSAIDs in 1999 [24], com-
pared to 14.15 million in 1998 [13]).
One of the five NSAIDs (ibuprofen) is available without
prescription (often referred to as over-the-counter
(OTC)), but we did not monitor how OTC sales of ibu-
profen have changed since the release of celecoxib and
rofecoxib. Were OTC sales of ibuprofen to have increased
over the 6 year period then this, rather than the release of
celecoxib and rofecoxib, could account for some of the
reduction in ibuprofen prescriptions. This in turn would
however mean that the level of NSAID volume would
have increased by an even greater amount than that esti-
mated in this study.
Finally, readers should be aware that rofecoxib has
recently been withdrawn from the market by its manufac-
turer Merck [25]. This was due to evidence of an increased
risk of serious coronary heart disease when taking
rofecoxib, particularly at high dosages and for prolonged
periods [26,27]. Some studies (e.g. [28]), but not others
(e.g. [29]), have also found that the use of celecoxib
increases a person's risk of coronary heart disease. How-
ever, after considering all available evidence, the US FDA
decided to not to withdraw celecoxib and other selective
COX-2 inhibitors from the market [30]. Given that
rofecoxib was withdrawn after the period for which data
were collected within this study we do not believe that this
impinges on the results of this study. Indeed celecoxib and
rofecoxib were the main two selective COX-2 inhibitors in
England in 2004, accounting for 74% of NHS expenditure
on selective COX-2 inhibitors [1]. Moreover, it was the
evidence of increased risk of coronary heart disease in a
group for which the rofecoxib was not originally intended
(bowel cancer patients) that led to its withdrawal [26].
Conclusion
It has been shown that the introduction of celecoxib and
rofecoxib coincided with a reduction in the total number
of prescriptions for diclofenac, ibuprofen and naproxen.
However, between January 1999 and September 2004,
overall prescription volume for the five NSAIDs increased
by 0.76 million items, and expenditure was estimated to
have increased by £20.4 million per quarter more than
would have been expected if overall NSAID volume had
remained constant. This suggests that celecoxib and
rofecoxib may have leaked to population groups who
would not previously have received a NSAID.Cost Effectiveness and Resource Allocation 2006, 4:9 http://www.resource-allocation.com/content/4/1/9
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